Insider Selling: Sangamo Therapeutics Inc (SGMO) VP Sells 5,000 Shares of Stock

Sangamo Therapeutics Inc (NASDAQ:SGMO) VP Edward R. Conner sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, January 7th. The stock was sold at an average price of $12.33, for a total value of $61,650.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Edward R. Conner also recently made the following trade(s):

  • On Thursday, December 6th, Edward R. Conner sold 5,000 shares of Sangamo Therapeutics stock. The stock was sold at an average price of $11.49, for a total value of $57,450.00.
  • On Tuesday, November 6th, Edward R. Conner sold 5,000 shares of Sangamo Therapeutics stock. The shares were sold at an average price of $13.73, for a total value of $68,650.00.

Shares of SGMO stock opened at $10.99 on Friday. Sangamo Therapeutics Inc has a 1-year low of $9.00 and a 1-year high of $27.50. The stock has a market cap of $1.12 billion, a P/E ratio of -15.70 and a beta of 2.72. The company has a debt-to-equity ratio of 0.07, a quick ratio of 6.32 and a current ratio of 6.32.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. Sangamo Therapeutics had a negative return on equity of 22.06% and a negative net margin of 88.78%. The company had revenue of $23.56 million for the quarter, compared to the consensus estimate of $26.96 million. During the same quarter last year, the company earned ($0.15) earnings per share. The firm’s revenue for the quarter was up 99.5% compared to the same quarter last year. On average, equities analysts anticipate that Sangamo Therapeutics Inc will post -0.72 earnings per share for the current fiscal year.

Several analysts recently weighed in on the company. BidaskClub lowered Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 9th. Wedbush set a $11.00 price target on Sangamo Therapeutics and gave the company a “hold” rating in a research note on Monday, November 19th. Guggenheim started coverage on Sangamo Therapeutics in a research report on Tuesday, October 9th. They set a “buy” rating and a $18.00 price objective on the stock. Finally, ValuEngine raised Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, November 1st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Sangamo Therapeutics currently has an average rating of “Buy” and an average target price of $18.83.

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. boosted its holdings in Sangamo Therapeutics by 20.8% in the second quarter. BlackRock Inc. now owns 8,083,121 shares of the biopharmaceutical company’s stock worth $114,780,000 after acquiring an additional 1,391,067 shares in the last quarter. Wasatch Advisors Inc. boosted its holdings in Sangamo Therapeutics by 12.0% in the third quarter. Wasatch Advisors Inc. now owns 4,544,596 shares of the biopharmaceutical company’s stock worth $77,031,000 after acquiring an additional 486,429 shares in the last quarter. Credit Suisse AG boosted its holdings in Sangamo Therapeutics by 23.5% in the third quarter. Credit Suisse AG now owns 2,184,505 shares of the biopharmaceutical company’s stock worth $37,027,000 after acquiring an additional 415,764 shares in the last quarter. Tocqueville Asset Management L.P. boosted its holdings in Sangamo Therapeutics by 108.6% in the third quarter. Tocqueville Asset Management L.P. now owns 711,237 shares of the biopharmaceutical company’s stock worth $12,055,000 after acquiring an additional 370,297 shares in the last quarter. Finally, Nexthera Capital LP boosted its holdings in Sangamo Therapeutics by 35.7% in the second quarter. Nexthera Capital LP now owns 1,066,914 shares of the biopharmaceutical company’s stock worth $15,150,000 after acquiring an additional 280,538 shares in the last quarter. 63.13% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Sangamo Therapeutics Inc (SGMO) VP Sells 5,000 Shares of Stock” was reported by WKRB News and is owned by of WKRB News. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.wkrb13.com/2019/01/11/insider-selling-sangamo-therapeutics-inc-sgmo-vp-sells-5000-shares-of-stock.html.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Recommended Story: How does a reverse stock split work?

Insider Buying and Selling by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply